FDA says proposed Phase 2 clinical trial may proceed

SOUTHLAKE, Texas–(BUSINESS WIRE)–OncoNano
Medicine, Inc. today announced that the U.S. Food and Drug
Administration (FDA) has accepted its Investigational New Drug (IND)
application for ONM-100, an intravenously administered imaging agent to
detect tumors and metastatic lymph nodes in solid cancers during
surgery. In addition, OncoNano received Fast Track designation from the
FDA for ONM-100.

ONM-100 is the first product from a platform based upon the OncoNano’s
library of unique micelles that respond to pH variability. Specifically,
ONM-100 is delivered to the tumor and subsequently fluoresces in the
acidic tumor microenvironment, which will allow surgeons to visualize
the tumor during surgery using existing infrared-based surgical cameras.
The OncoNano micelle platform is also being used to develop
therapeutics, cancer nanovaccines and immune therapies. OncoNano is
currently concluding the Phase 1 clinical trial for ONM-100 in the
Netherlands.

“These two positive responses from the FDA reflect the progress that we
have made on ONM-100,” said Kathy Rath, Vice President, Regulatory
Affairs at OncoNano Medicine. “The Fast Track designation will allow us
to have an ongoing, open dialogue with the FDA with the goal to make
this important technology available to surgeons and their patients at
the earliest possible time.”

“We are excited for the opportunity to work closely with the FDA while
developing this critical solution to the problems surgeons face every
day,” said Yalia Jayalakshmi, Vice President, Clinical Development at
OncoNano Medicine. “With these responses and the emerging clinical data
demonstrating the potential of the product in multiple types of solid
tumors, including breast, head and neck, esophageal and colorectal
cancers, we are well positioned to advance ONM-100 into a Phase 2
clinical study in 2019.”

More information on the FDA’s Fast Track designation can be found here.

About OncoNano Medicine
OncoNano Medicine is developing a
new class of pH-activated compounds that digitalize and exploit the
variability of pH in disease. pH variability is a proven, simple and
effective identifier of diseased tissue providing a foundation for the
development of a broad range of highly targeted therapeutics and imaging
agents. OncoNano is the first company to advance product candidates
using pH as a biomarker for cancer immunotherapy, therapeutic use and
intra-operative imaging based on its pH-sensitive micelle technology.
www.onconanomed.com

Contacts

MacDougall Biomedical Communications
Lauren Arnold, 781-235-3060
larnold@macbiocom.com